RxDoctor Payments Data

Windy Mitchell

Physician Assistant · Utica, NYNPI 1487613667

Payments from drug & device makers

$10,796in general payments, 2019–2025

Across 555 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • E.r. Squibb & Sons, L.L.C.$751
  • AstraZeneca$596
  • Johnson & Johnson$576
  • Amgen$556
  • Genentech USA, Inc.$542
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$8,72481%
  • Education$1,47314%
  • Other$5986%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis44$1,109
E.r. Squibb & Sons, L.L.C.68$751
AstraZeneca(2 entities)29$596
Johnson & Johnson(2 entities)32$576
Amgen23$556
Genentech USA, Inc.40$542
Daiichi Sankyo Inc.24$513
Merck24$459
Takeda Pharmaceuticals U.S.A., Inc.17$451
Regeneron Healthcare Solutions, Inc.13$309
Seagen Inc.10$293
Sanofi13$280
Bristol Myers Squibb27$262
Sanofi-aventis U.S. LLC3$260
Incyte Corporation8$249
Pfizer16$247
AbbVie9$246
Myriad Genetic Laboratories, Inc.10$225
Gilead(2 entities)12$218
Pharmacyclics LLC, An Abbvie Company9$185
AVEO Pharmaceuticals, Inc.6$185
ADC Therapeutics America, Inc.10$180
Eisai Inc.8$161
Epizyme, Inc.3$132
Genmab U.S., Inc.6$131
Sobi, Inc3$124
Karyopharm Therapeutics Inc.6$114
Lilly USA, LLC7$98
Astellas Pharma US Inc5$96
GSK5$94
Pharmacosmos Therapeutics Inc.5$92
EMD Serono, Inc.4$81
Array Biopharma Inc6$79
Puma Biotechnology, Inc.4$79
Taiho Oncology, Inc.4$64
Coherus Oncology, Inc.3$58
Servier Pharmaceuticals LLC3$50
Foundation Medicine, Inc.2$46
Ipsen Biopharmaceuticals, Inc2$42
Beigene USA, Inc.2$42
Geron Corporation2$42
Morphosys, US Inc.2$40
Bayer2$36
Blueprint Medicines Corporation2$32
Dendreon Pharmaceuticals LLC2$31
Dova Pharmaceuticals2$29
Azurity Pharmaceuticals, Inc.1$24
Recordati_rare_diseases_inc.1$24
Acrotech Biopharma Inc.1$23
Stemline Therapeutics Inc.1$22
Apellis Pharmaceuticals, Inc.1$21
Kyowa Kirin, Inc.1$20
Agios Pharmaceuticals, Inc.1$19
Deciphera Pharmaceuticals Inc.1$18
Jazz Pharmaceuticals Inc.1$17
Grifols USA, LLC1$17
Clovis Oncology, Inc.1$15
Springworks Therapeutics, Inc.1$14
Exelixis Inc.1$13
Global Blood Therapeutics, Inc.1$13

How this compares

$10,796 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$40,342
Medicare patients
271
Services billed
822

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib34$740,204
TasignaNilotinib Hcl25$331,075
XtandiEnzalutamide18$255,554
JakafiRuxolitinib Phosphate11$188,060
TagrissoOsimertinib Mesylate11$183,796
DopteletAvatrombopag Maleate13$161,340
Somatuline DepotLanreotide Acetate12$99,830
ProcritEpoetin Alfa26$95,847
XareltoRivaroxaban29$42,398
EliquisApixaban41$37,496
JanuviaSitagliptin Phosphate12$11,087
Everolimus13$7,163
Exemestane15$3,172
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen55$1,919
Hydroxyurea65$1,771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$185$740,20434 claims
NovartisTasigna$1,109$331,07525 claims
Astellas Pharma US IncXtandi$96$255,55418 claims
Incyte CorporationJakafi$249$188,06011 claims
AstraZenecaTagrisso$596$183,79611 claims
Dova PharmaceuticalsDoptelet$29$161,34013 claims
Johnson & JohnsonProcrit, Xarelto$576$138,24555 claims
Ipsen Biopharmaceuticals, IncSomatuline Depot$42$99,83012 claims
PfizerEliquis$247$37,49641 claims
MerckJanuvia$459$11,08712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Utica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →